Navigation Links
Rare genetic variations may account for severe reaction to LABA drugs in some people
Date:1/27/2014

Winston-Salem, N.C. Jan. 27, 2014 More than 25 million people in the United States have asthma, a chronic lung disease that inflames and narrows the airways causing recurring periods of wheezing, chest tightness, shortness of breath and coughing.

Although several types of drugs are available to treat asthma, long-acting beta agonists (LABAs) are among the most commonly used and work well for most people. However, for a small subgroup of people with asthma, LABAs can cause severe, life-threatening side effects and carry a boxed safety warning from the U.S. Food and Drug Administration. The dilemma for doctors and researchers has been in determining who is at risk of a severe reaction to the drug so that alternative medications can be prescribed.

"This severe reaction only occurs in a very small percentage of people who have asthma, and we don't know what makes these people different from those who do well on this therapy," said Eugene Bleecker, M.D., director of the Center for Genomics and Personalized Medicine Research at Wake Forest Baptist Medical Center and senior author of the study, which is published in the Jan. 27 issue of Lancet Respiratory Medicine.

"We hypothesized that rare gene variants would account for uncommon and severe adverse responses to long-acting beta agonists. Because these variants occur less frequently, they have the potential to have a stronger influence on drug response." In the National Institutes of Health-funded study, researchers at Wake Forest Baptist identified and evaluated six rare gene variants within the beta2-adrenergic receptor gene, the gene that may influence the response to beta agonist drugs. These rare variants were found through the sequencing of DNA from blood samples of 191 non-Hispanic white, 197 African-American and 73 Puerto Rican asthma patients. The researchers found that African-American asthma patients had five rare variants, a far greater number compared to non-Hispanic white patients who only had one variant. The Puerto Rican patients had one variant, which had previously only been identified in African-Americans.

"Looking at different ethnic groups provides an opportunity to study rare variants that come with different ethnic ancestries. In general, older ancestral populations, such as Africans, have a higher frequency of rare genetic variants that could account for differences in responses to LABAs," said Victor Ortega, M.D., a pulmonary disease specialist at Wake Forest Baptist and first author of the study.

The researchers then evaluated 1,209 asthma patients to determine the impact of these variants on the risk of hospital admission for a severe asthma episode in the past year. They found that these rare variants significantly increased the risk for a hospital admission in asthma patients treated with a long-acting beta agonist. This association was not observed in those who were not treated with the drugs. Further analysis was conducted on two variants for effects on additional health-care related outcomes. The research team found that these variants significantly increased urgent outpatient visits and treatment with oral or injectable steroids because of increased asthma symptoms in patients treated with a long-acting beta agonist.

Finally, the team looked at data on asthma symptoms and found non-Hispanic whites who had a rare variant were more than twice as likely to have uncontrolled symptoms during LABA therapy. The finding was replicated in a separate group of 516 non-Hispanic whites who were treated with LABAs at 12- and 24-month follow-up visits.

Non-Hispanic whites from both the primary and replication groups with this rare variant were more than twice as likely to experience uncontrolled, persistent symptoms during treatment with a long-acting beta agonist.

The research team concluded that screening for these rare variants is not recommended at this time until further research can be conducted to validate the group's findings. However, genetic testing may be helpful for severe asthmatics that are being treated with multiple therapies, including high-dose inhaled steroid and long-acting beta agonists, and are still uncontrolled and very symptomatic, according to Bleecker and Ortega.

With additional research, there is the potential to identify genetic biomarkers that could predict the best treatment option for people with asthma, a goal of personalized medicine, the authors said.


'/>"/>

Contact: Marguerite Beck
marbeck@wakehealth.edu
336-716-2415
Wake Forest Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Head, Body Lice Are Genetically Very Similar
4. Certain Genetic Regions May Be Tied to Osteoporosis
5. Study of half siblings provides genetic clues to autism
6. Genetic variants, tobacco exposure and lung cancer risk
7. Research Gets Closer to Genetic Roots of Glaucoma
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
10. Some women may be genetically predisposed to smoking-related hot flashes
11. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... VitreosHealth ... each Medicare Advantage member’s risk, identify any gaps-in-coding, as well as gaps-in-care ... transform the HCC Risk Adjustment process from a typical fragmented process to ...
(Date:2/22/2017)... Fla. (PRWEB) , ... February 22, 2017 , ... ... is just as effective on smaller and sometimes harder to reach ones, according ... were presented at the International Stroke Conference in Houston by Ricardo A. Hanel, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the ... national TV host Tom Seay and his production crew. Tom Seay’s program “Best ... around the world. Saddle Sidekicks will be featured on April 6, 2017. After ...
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of the internet, IdrisArkette.com ... checklist. Over a period of just 24 months, thousands of individuals interested in a ... called T.A.D. , “The internet is not getting quieter. In fact it’s becoming noisier ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management ... on the App Store and Google Play . Florida-based Sober Network, ... and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... Sales, ASPs, Market Value & Growth Trends - ... - Competitive Analysis for each chapter segment - ... Download the full report: https://www.reportbuyer.com/product/4665946/ ... use different delivery methods: articulated arm lasers, fiber-delivered ...
(Date:2/22/2017)... Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), today announced its ... December 31, 2016. ... This news release should be read in ... and analysis for the years ended December 31, 2016 and ... at www.sedar.com and on the Company,s website at ...
(Date:2/22/2017)... 22, 2017 Summary Provides ... and agreements entered into by the worlds leading ... http://www.reportlinker.com/p03605675-summary/view-report.html Description The Global Atherosclerosis Partnering ... and access to partnering deals and agreements entered ... - Trends in partnering deals - ...
Breaking Medicine Technology: